Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults

Ryan A. Harris, Jennifer Pedersen-White, De Huang Guo, Inger S. Stallmann-Jorgensen, Daniel Keeton, Ying Huang, Yashesh Shah, Haidong Zhu, Yanbin Dong

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

BackgroundA growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000IU monthly supplementation of oral vitamin D3 would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.MethodsA randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.ResultsFollowing 16 weeks of placebo (n = 23; mean age 31±2 years) or 60,000 IU monthly oral vitamin D3 (n = 22; mean age 29±2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2±3.0 to 48.7±3.2nmol/l and 34.3±2.2 to 100.9±6.6nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8±1.3%), whereas the placebo group had no change (-1.3± 0.6%). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005±0.004cm) and FMD/shear (0.08 ±0.04%/s-1, area under the curve (AUC) × 103) following treatment, whereas no change (-0.005± 0.002cm and-0.02± 0.02%/s 1, AUC, respectively) was observed following placebo.ConclusionSupplementation of 60,000IU monthly oral vitamin D3 (∼2,000IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.

Original languageEnglish (US)
Pages (from-to)557-562
Number of pages6
JournalAmerican Journal of Hypertension
Volume24
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Cholecalciferol
African Americans
Dilatation
Placebos
Vitamin D
Vitamin D Deficiency
Area Under Curve
Cardiovascular Diseases
Serum
Calcium
Controlled Clinical Trials
Parathyroid Hormone
Blood Vessels
Creatinine
Therapeutics
Urine

Keywords

  • African American
  • blood pressure
  • cardiovascular disease
  • endothelial function
  • hypertension
  • vitamin D

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. / Harris, Ryan A.; Pedersen-White, Jennifer; Guo, De Huang; Stallmann-Jorgensen, Inger S.; Keeton, Daniel; Huang, Ying; Shah, Yashesh; Zhu, Haidong; Dong, Yanbin.

In: American Journal of Hypertension, Vol. 24, No. 5, 01.05.2011, p. 557-562.

Research output: Contribution to journalArticle

Harris, Ryan A. ; Pedersen-White, Jennifer ; Guo, De Huang ; Stallmann-Jorgensen, Inger S. ; Keeton, Daniel ; Huang, Ying ; Shah, Yashesh ; Zhu, Haidong ; Dong, Yanbin. / Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. In: American Journal of Hypertension. 2011 ; Vol. 24, No. 5. pp. 557-562.
@article{1121bfc3cb3b456c826be6b7eb873fa5,
title = "Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults",
abstract = "BackgroundA growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000IU monthly supplementation of oral vitamin D3 would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.MethodsA randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.ResultsFollowing 16 weeks of placebo (n = 23; mean age 31±2 years) or 60,000 IU monthly oral vitamin D3 (n = 22; mean age 29±2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2±3.0 to 48.7±3.2nmol/l and 34.3±2.2 to 100.9±6.6nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8±1.3{\%}), whereas the placebo group had no change (-1.3± 0.6{\%}). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005±0.004cm) and FMD/shear (0.08 ±0.04{\%}/s-1, area under the curve (AUC) × 103) following treatment, whereas no change (-0.005± 0.002cm and-0.02± 0.02{\%}/s 1, AUC, respectively) was observed following placebo.ConclusionSupplementation of 60,000IU monthly oral vitamin D3 (∼2,000IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.",
keywords = "African American, blood pressure, cardiovascular disease, endothelial function, hypertension, vitamin D",
author = "Harris, {Ryan A.} and Jennifer Pedersen-White and Guo, {De Huang} and Stallmann-Jorgensen, {Inger S.} and Daniel Keeton and Ying Huang and Yashesh Shah and Haidong Zhu and Yanbin Dong",
year = "2011",
month = "5",
day = "1",
doi = "10.1038/ajh.2011.12",
language = "English (US)",
volume = "24",
pages = "557--562",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults

AU - Harris, Ryan A.

AU - Pedersen-White, Jennifer

AU - Guo, De Huang

AU - Stallmann-Jorgensen, Inger S.

AU - Keeton, Daniel

AU - Huang, Ying

AU - Shah, Yashesh

AU - Zhu, Haidong

AU - Dong, Yanbin

PY - 2011/5/1

Y1 - 2011/5/1

N2 - BackgroundA growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000IU monthly supplementation of oral vitamin D3 would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.MethodsA randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.ResultsFollowing 16 weeks of placebo (n = 23; mean age 31±2 years) or 60,000 IU monthly oral vitamin D3 (n = 22; mean age 29±2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2±3.0 to 48.7±3.2nmol/l and 34.3±2.2 to 100.9±6.6nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8±1.3%), whereas the placebo group had no change (-1.3± 0.6%). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005±0.004cm) and FMD/shear (0.08 ±0.04%/s-1, area under the curve (AUC) × 103) following treatment, whereas no change (-0.005± 0.002cm and-0.02± 0.02%/s 1, AUC, respectively) was observed following placebo.ConclusionSupplementation of 60,000IU monthly oral vitamin D3 (∼2,000IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.

AB - BackgroundA growing body of evidence has linked vitamin D deficiency to increased risk of cardiovascular disease. Vitamin D deficiency is also more common in African Americans for whom an increased cardiovascular disease risk exists. This study sought to test the hypothesis that 16 weeks of 60,000IU monthly supplementation of oral vitamin D3 would improve flow-mediated dilation (FMD) in African Americans, whereas no change would be observed in the placebo group.MethodsA randomized, double-blind, placebo-controlled clinical trial was conducted. Fifty-seven African-American adults were randomly assigned to either the placebo group or vitamin D group.ResultsFollowing 16 weeks of placebo (n = 23; mean age 31±2 years) or 60,000 IU monthly oral vitamin D3 (n = 22; mean age 29±2 years), serum concentrations of 25-hydroxyvitamin D (25(OH)D) increased from 38.2±3.0 to 48.7±3.2nmol/l and 34.3±2.2 to 100.9±6.6nmol/l, respectively. No changes in serum parathyroid hormone (PTH), serum calcium, or urine calcium/creatinine were observed following either treatment. Following 16 weeks of treatment, significant improvements in FMD were only observed in the vitamin D group (1.8±1.3%), whereas the placebo group had no change (-1.3± 0.6%). Similarly, the vitamin D group exhibited an increase in absolute change in diameter (0.005±0.004cm) and FMD/shear (0.08 ±0.04%/s-1, area under the curve (AUC) × 103) following treatment, whereas no change (-0.005± 0.002cm and-0.02± 0.02%/s 1, AUC, respectively) was observed following placebo.ConclusionSupplementation of 60,000IU monthly oral vitamin D3 (∼2,000IU/day) for 16 weeks is effective at improving vascular endothelial function in African-American adults.

KW - African American

KW - blood pressure

KW - cardiovascular disease

KW - endothelial function

KW - hypertension

KW - vitamin D

UR - http://www.scopus.com/inward/record.url?scp=79954729172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954729172&partnerID=8YFLogxK

U2 - 10.1038/ajh.2011.12

DO - 10.1038/ajh.2011.12

M3 - Article

C2 - 21311504

AN - SCOPUS:79954729172

VL - 24

SP - 557

EP - 562

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 5

ER -